Braveheart Bio, Inc.

BRVE

NASDAQHealthcareBiotechnology

在 GoAI 中打开

收盘时

US$27.45

+US$0.74 · +2.77%

9月16日 16:00 ET

公司概况

公司网站

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Travis Murdoch
上市以来: 2026年8月6日
雇员: 49

市场位置

日内区间

当前US$27.45，

US$26.22US$28.90

52周区间

当前US$27.45，

US$24.31US$32.00

开盘价: US$26.82
前收盘价: US$26.71
成交量: 55.07万; 1.25× 平均值
平均成交量: 44.06万; 日均成交量
市值: 19.39亿 USD
贝塔: 0; 市场参考 1
50天平均值: US$27.3482; 高于平均水平+0.37%
200天平均值: US$27.3482; 高于平均水平+0.37%

分析师评级

第三方分析师预期可能变化，并非 GoAI 建议。

分析师目标价

平均目标

US$45.25

上涨空间 64.85%

过去 12 个月12个月预测最高：US$48.00平均的：US$45.25最低：US$40.00

BRVE 消息

globenewswire.com2026年9月16日

Braveheart Bio to Participate in Stifel Cardiometabolic Forum

SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other…

阅读源码

globenewswire.com2026年9月8日

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effect to Braveheart…

阅读源码

globenewswire.com2026年9月1日

Braveheart Bio to Participate in Cantor Global Healthcare Conference

SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other…

阅读源码

fool.com2026年8月10日

Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?

The transaction involved 27,777 shares acquired for ~$500,000 on August 7, 2026. The acquisition increased the total equity position by 5%, resulting in a 0.87% ownership stake.

阅读源码

fool.com2026年8月10日

Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?

The transaction involved 83,333 shares with an estimated value of ~$1.5 million as of the August 7, 2026 market close. Director Viehbacher increased his direct equity holdings by 16% through this acquisition.

阅读源码

fool.com2026年8月10日

Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?

Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 million, representing a 13% stake.

阅读源码